{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:05:56Z","timestamp":1791338756816,"version":"4.3.1"},"reference-count":145,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Knut and Alice Wallenberg Foundations"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>p53 is the major tumor suppressor and the most frequently inactivated gene in cancer. p53 could be disabled either by mutations or by upstream negative regulators, including, but not limited to MDM2 and MDMX. p53 activity is required for the prevention as well as for the eradication of cancers. Restoration of p53 activity in mouse models leads to the suppression of established tumors of different origin. These findings provide a strong support to the anti-cancer strategy aimed for p53 reactivation. In this review, we summarize recent progress in the development of small molecules, which restore the tumor suppressor function of wild-type p53 and discuss their clinical advance. We discuss different aspects of p53-mediated response, which contribute to suppression of tumors, including non-canonical p53 activities, such as regulation of immune response. While targeting p53 inhibitors is a very promising approach, there are certain limitations and concerns that the intensive research and clinical evaluation of compounds will hopefully help to overcome.<\/jats:p>","DOI":"10.1093\/jmcb\/mjz075","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T15:09:21Z","timestamp":1562339361000},"page":"586-599","source":"Crossref","is-referenced-by-count":128,"title":["Inhibition of p53 inhibitors: progress, challenges and perspectives"],"prefix":"10.1093","volume":"11","author":[{"given":"Gema","family":"Sanz","sequence":"first","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Biomedicum 8C, Karolinska Institute, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Biomedicum 8C, Karolinska Institute, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Peuget","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Biomedicum 8C, Karolinska Institute, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Selivanova","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Biomedicum 8C, Karolinska Institute, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"key":"2019091013081719000_ref1","doi-asserted-by":"crossref","first-page":"e02200","DOI":"10.7554\/eLife.02200","article-title":"Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms","volume":"3","author":"Allen","year":"2014","journal-title":"eLife"},{"key":"2019091013081719000_ref2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.chembiol.2011.08.018","article-title":"Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes","volume":"18","author":"Altun","year":"2011","journal-title":"Chem. Biol."},{"key":"2019091013081719000_ref13","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Amadou","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2019091013081719000_ref3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2019091013081719000_ref4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molcel.2018.01.023","article-title":"Mitochondrial MDM2 regulates respiratory complex I activity independently of p53","volume":"69","author":"Arena","year":"2018","journal-title":"Mol. Cell"},{"key":"2019091013081719000_ref5","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/onc.2011.185","article-title":"Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3","volume":"30","author":"Aziz","year":"2011","journal-title":"Oncogene"},{"key":"2019091013081719000_ref6","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"2019091013081719000_ref7","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1021\/ja0693587","article-title":"Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide","volume":"129","author":"Bernal","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"2019091013081719000_ref8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2010.10.024","article-title":"A stapled p53 helix overcomes HDMX-mediated suppression of p53","volume":"18","author":"Bernal","year":"2010","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/1947601912455331","article-title":"Mdm2 and MdmX as regulators of gene expression","volume":"3","author":"Biderman","year":"2012","journal-title":"Genes Cancer"},{"key":"2019091013081719000_ref10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-15-1522","article-title":"SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma","volume":"22","author":"Bill","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2019091013081719000_ref11","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","article-title":"A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans","volume":"119","author":"Bond","year":"2004","journal-title":"Cell"},{"key":"2019091013081719000_ref14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.21037\/tcr.2016.11.76","article-title":"Regulation of cytotoxic T-cell responses by p53 in cancer","volume":"5","author":"Braun","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"2019091013081719000_ref15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/cb3005148","article-title":"Stapled peptides with improved potency and specificity that activate p53","volume":"8","author":"Brown","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"2019091013081719000_ref16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"key":"2019091013081719000_ref17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","article-title":"Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53","volume":"22","author":"Bywater","year":"2012","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref18","doi-asserted-by":"crossref","first-page":"30487","DOI":"10.18632\/oncotarget.5890","article-title":"Synergistic\neffects of p53 activation via MDM2 inhibition in combination with inhibition\nof Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells","volume":"6","author":"Carter","year":"2015","journal-title":"Oncotarget"},{"key":"2019091013081719000_ref19","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref20","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1073\/pnas.1620262114","article-title":"Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf\u2212\/\u2212 mouse model","volume":"114","author":"Chapeau","year":"2017","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A\nsmall molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis\nin multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref22","first-page":"263","article-title":"Seeking synergy in p53 transcriptional activation for cancer therapy","volume":"14","author":"Cheok","year":"2012","journal-title":"Discov. Med."},{"key":"2019091013081719000_ref23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1541-7786.MCR-07-0161","article-title":"Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination","volume":"5","author":"Cheok","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"2019091013081719000_ref24","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/cdd.2010.18","article-title":"Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53","volume":"17","author":"Cheok","year":"2010","journal-title":"Cell Death Differ."},{"key":"2019091013081719000_ref25","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.4161\/cc.8.17.9503","article-title":"Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy","volume":"8","author":"Choong","year":"2009","journal-title":"Cell Cycle"},{"key":"2019091013081719000_ref26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng1572","article-title":"Temporal dissection of p53 function in vitro and in vivo","volume":"37","author":"Christophorou","year":"2005","journal-title":"Nat. Genet."},{"key":"2019091013081719000_ref27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1535-7163.MCT-09-0097","article-title":"Small-molecule inhibitor of USP7\/HAUSP ubiquitin protease stabilizes and activates p53 in cells","volume":"8","author":"Colland","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"2019091013081719000_ref28","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.1600789","article-title":"An unbiased linkage approach reveals that the p53 pathway is coupled to NK cell maturation","volume":"199","author":"Collin","year":"2017","journal-title":"J. Immunol."},{"key":"2019091013081719000_ref29","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl Cancer Inst."},{"key":"2019091013081719000_ref30","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/ijms17111942","article-title":"Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor\nmicroenvironment","volume":"17","author":"Cui","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"2019091013081719000_ref31","doi-asserted-by":"crossref","DOI":"10.1038\/nature02501","article-title":"Tumour\nsuppression: disruption of HAUSP gene stabilizes p53","volume":"428","author":"Cummins","year":"2004","journal-title":"Nature"},{"key":"2019091013081719000_ref32","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1038\/sj.onc.1204741","article-title":"Common and reversible regulation of wild-type\np53 function and of ribosomal biogenesis by protein kinases in human cells","volume":"20","author":"David-Pfeuty","year":"2001","journal-title":"Oncogene"},{"key":"2019091013081719000_ref33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"2019091013081719000_ref34","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0959-8049(16)30169-1","article-title":"A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors","volume":"51","author":"de Weger","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"2019091013081719000_ref35","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/1947601911409737","article-title":"The ribosomal protein-Mdm2-p53 pathway and energy metabolism: bridging the gap between feast and famine","volume":"2","author":"Deisenroth","year":"2011","journal-title":"Genes Cancer"},{"key":"2019091013081719000_ref36","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction","volume":"49","author":"Ding","year":"2006","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref37","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref144a","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jmcb\/mjx051","article-title":"p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a","volume":"10","author":"Duan","year":"2018","journal-title":"J. Mol. Cell Biol."},{"key":"2019091013081719000_ref38","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1158\/0008-5472.CAN-07-0200","article-title":"Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin","volume":"67","author":"Efeyan","year":"2007","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jmcb\/mjw052","article-title":"Role of Mdm2 and Mdmx in DNA repair","volume":"9","author":"Eischen","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"2019091013081719000_ref40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2009.01.019","article-title":"MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53","volume":"15","author":"Enge","year":"2009","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref41","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1073\/pnas.0508476103","article-title":"Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo","volume":"103","author":"Francoz","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref42","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1128\/MCB.18.12.7288","article-title":"Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6","volume":"18","author":"Freedman","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"2019091013081719000_ref43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/nar\/gkt944","article-title":"The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing","volume":"42","author":"Frum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"2019091013081719000_ref44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002530","article-title":"Curaxins: anticancer compounds that simultaneously suppress NF-\u03baB and activate p53 by targeting FACT","volume":"3","author":"Gasparian","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2019091013081719000_ref45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"2019091013081719000_ref46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm049137g","article-title":"Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells","volume":"48","author":"Grasberger","year":"2005","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref47","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1073\/pnas.1203789109","article-title":"Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization","volume":"109","author":"Graves","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref75","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2016.08.015","article-title":"Discovery of dual inhibitors of MDM2 and XIAP for cancer treatment","volume":"30","author":"Gu","year":"2016","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref48","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1158\/0008-5472.CAN-16-2832","article-title":"Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity","volume":"77","author":"Guo","year":"2017","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref49","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-03-1541","article-title":"p53 pathway in renal cell carcinoma is repressed by a dominant mechanism","volume":"64","author":"Gurova","year":"2004","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2159-8290.CD-11-0104","article-title":"Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay","volume":"1","author":"Herman","year":"2011","journal-title":"Cancer Discov."},{"key":"2019091013081719000_ref51","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1074\/jbc.M113.487736","article-title":"A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer","volume":"289","author":"Hoffmann","year":"2014","journal-title":"J. Biol. Chem."},{"key":"2019091013081719000_ref52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1186\/s12885-017-3627-4","article-title":"XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis","volume":"17","author":"Hussain","year":"2017","journal-title":"BMC Cancer"},{"key":"2019091013081719000_ref53","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20130783","article-title":"p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells","volume":"210","author":"Iannello","year":"2013","journal-title":"J. Exp. Med."},{"key":"2019091013081719000_ref54","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1158\/0008-5472.CAN-17-0949","article-title":"Predictive gene signatures determine tumor sensitivity to MDM2 inhibition","volume":"78","author":"Ishizawa","year":"2018","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref55","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"key":"2019091013081719000_ref56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10637-014-0090-9","article-title":"PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines","volume":"32","author":"Izetti","year":"2014","journal-title":"Invest. New Drugs"},{"key":"2019091013081719000_ref57","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06498","article-title":"A distinct p53 target gene set predicts for response to the selective p53\u2013HDM2 inhibitor NVP-CGM097","volume":"4","author":"Jeay","year":"2015","journal-title":"eLife"},{"key":"2019091013081719000_ref58","doi-asserted-by":"crossref","first-page":"12609","DOI":"10.1038\/ncomms12609","article-title":"TP53\nmutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma","volume":"7","author":"Jung","year":"2016","journal-title":"Nat. Commun."},{"key":"2019091013081719000_ref59","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"2019091013081719000_ref60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature24006","article-title":"USP7\nsmall-molecule inhibitors interfere with ubiquitin binding","volume":"550","author":"Kategaya","year":"2017","journal-title":"Nature"},{"key":"2019091013081719000_ref61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging\nthe p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Khoo","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"2019091013081719000_ref62","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.1073\/pnas.0910885107","article-title":"Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway","volume":"107","author":"Khutornenko","year":"2010","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref63","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.4161\/cc.8.22.10121","article-title":"Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A","volume":"8","author":"Korotchkina","year":"2009","journal-title":"Cell Cycle"},{"key":"2019091013081719000_ref64","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41467-018-03441-3","article-title":"A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage","volume":"9","author":"Ladds","year":"2018","journal-title":"Nat.\nCommun."},{"key":"2019091013081719000_ref65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","article-title":"Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator","volume":"13","author":"Lain","year":"2008","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref66","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational\nheterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"2019091013081719000_ref67","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.4161\/cc.10.19.17630","article-title":"Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2","volume":"10","author":"Li","year":"2011","journal-title":"Cell Cycle"},{"key":"2019091013081719000_ref68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4161\/onci.19409","article-title":"A novel facet of tumor suppression by p53: induction of tumor immunogenicity","volume":"1","author":"Li","year":"2012","journal-title":"Oncoimmunology"},{"key":"2019091013081719000_ref69","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/cdd.2014.212","article-title":"A unique role for p53 in the regulation of M2 macrophage polarization","volume":"22","author":"Li","year":"2015","journal-title":"Cell Death Differ."},{"key":"2019091013081719000_ref70","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"A dynamic role of HAUSP in the p53-Mdm2 pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol. Cell"},{"key":"2019091013081719000_ref71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","article-title":"Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2019091013081719000_ref72","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref73","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1158\/0008-5472.CAN-13-1070","article-title":"p53 and NF-\u03baB coregulate proinflammatory gene responses in human macrophages","volume":"74","author":"Lowe","year":"2014","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccr.2007.08.033","article-title":"The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop","volume":"12","author":"Lu","year":"2007","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell"},{"key":"2019091013081719000_ref77","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-8674(01)00524-4","article-title":"Negative control of p53 by Sir2\u03b1 promotes cell survival under stress","volume":"107","author":"Luo","year":"2001","journal-title":"Cell"},{"key":"2019091013081719000_ref78","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/15384101.2016.1160975","article-title":"cMyc\u2013p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response","volume":"15","author":"Madapura","year":"2016","journal-title":"Cell Cycle"},{"key":"2019091013081719000_ref79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/B978-0-12-380916-2.00003-6","article-title":"MDM2 and MDMX in cancer and development","volume":"94","author":"Marine","year":"2011","journal-title":"Curr. Top. Dev. Biol."},{"key":"2019091013081719000_ref80","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"Martins","year":"2006","journal-title":"Cell"},{"key":"2019091013081719000_ref81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1541-7786.MCR-17-0019","article-title":"The cytidine deaminase APOBEC3 family is subject to transcriptional regulation by p53","volume":"15","author":"Menendez","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"2019091013081719000_ref82","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.129","article-title":"Adaptation\nof cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant\ncancer cells","volume":"2","author":"Michaelis","year":"2011","journal-title":"Cell Death Dis."},{"key":"2019091013081719000_ref83","first-page":"919","article-title":"Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis","volume":"30","author":"Mizutani","year":"2007","journal-title":"Int. J. Oncol."},{"key":"2019091013081719000_ref84","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/carcin\/bgq101","article-title":"p53 is balancing development, differentiation and de-differentiation to assure cancer prevention","volume":"31","author":"Molchadsky","year":"2010","journal-title":"Carcinogenesis"},{"key":"2019091013081719000_ref85","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The\nMDM2 gene amplification database","volume":"26","author":"Momand","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"2019091013081719000_ref144","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jmcb\/mjx004","article-title":"Mdm proteins: critical regulators of embryogenesis and homoeostasis","volume":"9","author":"Moyer","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"2019091013081719000_ref86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fonc.2014.00197","article-title":"X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy","volume":"4","author":"Obexer","year":"2014","journal-title":"Front. Oncol."},{"key":"2019091013081719000_ref87","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/MCB.15.6.3032","article-title":"Wild-type human p53 and a temperature-sensitive mutant induce Fas\/APO-1 expression","volume":"15","author":"Owen-Schaub","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"2019091013081719000_ref88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","article-title":"A targeting modality for destruction of RNA polymerase I that possesses anticancer activity","volume":"25","author":"Peltonen","year":"2014","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamadermatol.2017.4584","article-title":"Association of immunotherapy with overall survival in elderly patients with melanoma","volume":"154","author":"Perier-Muzet","year":"2018","journal-title":"JAMA Dermatology"},{"key":"2019091013081719000_ref90","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet. Oncol."},{"key":"2019091013081719000_ref91","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1074\/jbc.M109.056747","article-title":"Identification and characterization of the first small molecule inhibitor of MDMX","volume":"285","author":"Reed","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2019091013081719000_ref92","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","article-title":"Acute myeloid leukemia patients\u2019 clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts","volume":"101","author":"Reis","year":"2016","journal-title":"Haematologica"},{"key":"2019091013081719000_ref93","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.chembiol.2012.02.007","article-title":"Discovery of specific inhibitors of human USP7\/HAUSP deubiquitinating enzyme","volume":"19","author":"Reverdy","year":"2012","journal-title":"Chem. Biol."},{"key":"2019091013081719000_ref94","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1021\/jm300354j","article-title":"Structure-based design of novel inhibitors of the MDM2\u2013p53 interaction","volume":"55","author":"Rew","year":"2012","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref95","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccr.2006.10.010","article-title":"Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo","volume":"10","author":"Ringshausen","year":"2006","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1087057108315038","article-title":"Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen","volume":"13","author":"Sasiela","year":"2008","journal-title":"J. Biomol. Screen."},{"key":"2019091013081719000_ref97","first-page":"5891","article-title":"An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides","volume-title":"J. Am. Chem. Soc.","author":"Schafmeister","year":"2000"},{"key":"2019091013081719000_ref98","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"2019091013081719000_ref99","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/cancers10060170","article-title":"The cellular p53 inhibitor MDM2 and the growth factor receptor FLT3 as biomarkers for treatment responses to the MDM2-inhibitor idasanutlin and the MEK1 inhibitor cobimetinib in acute myeloid leukemia","volume":"10","author":"Seipel","year":"2018","journal-title":"Cancers"},{"key":"2019091013081719000_ref100","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.febslet.2014.03.049","article-title":"Wild type p53 reactivation: from lab bench to clinic","volume":"588","author":"Selivanova","year":"2014","journal-title":"FEBS Lett."},{"key":"2019091013081719000_ref101","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref102","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1158\/0008-5472.CAN-11-4134","article-title":"The\nhuman TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells","volume":"72","author":"Shatz","year":"2012","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref103","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/cdd.2013.186","article-title":"ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis","volume":"21","author":"Shi","year":"2014","journal-title":"Cell Death Differ."},{"key":"2019091013081719000_ref104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The\nconsensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sj\u00f6blom","year":"2006","journal-title":"Science"},{"key":"2019091013081719000_ref105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/cdd.2009.136","article-title":"p53-mediated apoptosis prevents the accumulation of progenitor\nB cells and B-cell tumors","volume":"17","author":"Slatter","year":"2010","journal-title":"Cell Death Differ."},{"key":"2019091013081719000_ref106","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1112941","article-title":"Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12","volume":"5","author":"Slatter","year":"2016","journal-title":"Oncoimmunology"},{"key":"2019091013081719000_ref107","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/cdd.2011.45","article-title":"Abrogation\nof Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX","volume":"18","author":"Spinnler","year":"2011","journal-title":"Cell Death Differ."},{"key":"2019091013081719000_ref108","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nchembio.965","article-title":"ATM\nand MET kinases are synthetic lethal with nongenotoxic activation of p53","volume":"8","author":"Sullivan","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"2019091013081719000_ref109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4161\/15384101.2014.973330","article-title":"ATM\nregulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels","volume":"14","author":"Sullivan","year":"2015","journal-title":"Cell Cycle"},{"key":"2019091013081719000_ref110","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/jm401753e","article-title":"Discovery\nof AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor\nin clinical development","volume":"57","author":"Sun","year":"2014","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref111","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","article-title":"High\nexpression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia","volume":"10","author":"Tamm","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2019091013081719000_ref112","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2019091013081719000_ref113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jmcb\/mjw049","article-title":"Modulation of the p53\/MDM2 interplay by HAUSP inhibitors","volume":"9","author":"Tavana","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"2019091013081719000_ref114","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1158\/0008-5472.CAN-10-3211","article-title":"Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2","volume":"71","author":"Textor","year":"2011","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"2019091013081719000_ref116","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref117","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"key":"2019091013081719000_ref118","doi-asserted-by":"crossref","first-page":"44232","DOI":"10.18632\/oncotarget.17790","article-title":"Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists","volume":"8","author":"Urso","year":"2017","journal-title":"Oncotarget"},{"key":"2019091013081719000_ref119","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"2019091013081719000_ref120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo","volume":"445","author":"Ventura","year":"2007","journal-title":"Nature"},{"key":"2019091013081719000_ref121","doi-asserted-by":"crossref","first-page":"16906","DOI":"10.1073\/pnas.1215060109","article-title":"Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2","volume":"109","author":"Vogel","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2019091013081719000_ref122","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"2019091013081719000_ref123","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"2019091013081719000_ref124","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"2019091013081719000_ref125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"2019091013081719000_ref126","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2016.70.7117","article-title":"Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors","volume":"35","author":"Wagner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2019091013081719000_ref127","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"key":"2019091013081719000_ref128","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat. Commun."},{"key":"2019091013081719000_ref129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/1535-7163.MCT-10-0581","article-title":"A small-molecule inhibitor of MDMX activates p53 and induces apoptosis","volume":"10","author":"Wang","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"2019091013081719000_ref130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.1965","article-title":"CRISPR-Cas9-based target validation for p53-reactivating model compounds","volume":"12","author":"Wanzel","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"2019091013081719000_ref131","doi-asserted-by":"crossref","first-page":"a026211","DOI":"10.1101\/cshperspect.a026211","article-title":"Attenuating the p53 pathway in human cancers: many means to the same end","volume":"6","author":"Wasylishen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2019091013081719000_ref132","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.immuni.2014.04.006","article-title":"Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4+ T cell responses","volume":"40","author":"Watanabe","year":"2014","journal-title":"Immunity"},{"key":"2019091013081719000_ref133","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"2019091013081719000_ref134","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jmcb\/mjw046","article-title":"Mdm2 as a chromatin modifier","volume":"9","author":"Wienken","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"2019091013081719000_ref135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"2019091013081719000_ref136","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2005.04.029","article-title":"Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells","volume":"7","author":"Yang","year":"2005","journal-title":"Cancer Cell"},{"key":"2019091013081719000_ref137","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1021\/jm901400z","article-title":"Potent and orally active small-molecule inhibitors of the MDM2\u2212p53 interaction","volume":"52","author":"Yu","year":"2009","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref138","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/emmm.201100211","article-title":"A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53","volume":"4","author":"Zhang","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"2019091013081719000_ref139","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0092-8674(00)81401-4","article-title":"ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways","volume":"92","author":"Zhang","year":"1998","journal-title":"Cell"},{"key":"2019091013081719000_ref140","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/0008-5472.CAN-09-2787","article-title":"Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"2019091013081719000_ref141","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1021\/jm4005708","article-title":"A potent small-molecule inhibitor of the MDM2\u2013p53 interaction (MI-888) achieved complete and durable tumor regression in mice","volume":"56","author":"Zhao","year":"2013","journal-title":"J. Med. Chem."},{"key":"2019091013081719000_ref142","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1038\/sj.onc.1203235","article-title":"p53 induces TAP1 and enhances the transport of MHC class I peptides","volume":"18","author":"Zhu","year":"1999","journal-title":"Oncogene"},{"key":"2019091013081719000_ref143","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"}],"container-title":["Journal of Molecular Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jmcb\/advance-article-pdf\/doi\/10.1093\/jmcb\/mjz075\/29187815\/mjz075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jmcb\/article-pdf\/11\/7\/586\/29310294\/mjz075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T07:41:59Z","timestamp":1569051719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jmcb\/article\/11\/7\/586\/5532737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":145,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,8,20]]},"published-print":{"date-parts":[[2019,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jmcb\/mjz075","relation":{},"ISSN":["1759-4685"],"issn-type":[{"value":"1759-4685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,7]]}}}